wheelchair icon
mobile-menu
Image related to content

Clinical Trial

Narcolepsy Clinical Trial

Image related to content

The SAPPHIRE Clinical Trial is a research study in Tampa Bay of cleminorexton, an investigational drug being tested for narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). It’s open to adults 18 to 70 years old who have been diagnosed with NT1 or NT2. Meris Clinical Research is a study site in Brandon, Florida, serving the Tampa Bay area.

Call (813) 413-7218 or use the form on this page to see if you qualify.

Quick facts

ConditionNarcolepsy type 1 (NT1) and narcolepsy type 2 (NT2)
Main symptomsExcessive daytime sleepiness (EDS). People with NT1 also experience cataplexy.
Ages18 to 70 years old
LocationMeris Clinical Research – Brandon, 310 Oakfield Dr., Brandon, FL 33511
Study lengthScreening up to 7 weeks, treatment 12 weeks, safety follow-up 1 week
CostYou will not pay for the study drug or for any tests or procedures related to the study.
ReimbursementYou may be reimbursed for some costs, like meals and transportation.
StatusEnrolling

SEE IF YOU QUALIFY

What is the SAPPHIRE Clinical Trial?

The SAPPHIRE Clinical Trial is being run to learn more about cleminorexton, an investigational drug being tested for narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2).

What are narcolepsy type 1 and type 2?

NT1 and NT2 change how the brain controls sleep-wake cycles. One of the main symptoms of NT1 and NT2 is excessive daytime sleepiness, or EDS. People with EDS feel extreme drowsiness, making it hard to stay awake and alert during the day no matter how much sleep they got the night before.

People with NT1 also experience cataplexy. Cataplexy is a sudden loss of muscle strength. This can cause people to collapse or briefly lose control of their muscles. Strong emotions, such as laughter, surprise, sadness, or fear, can trigger cataplexy.

Why do we need another treatment?

NT1 and NT2 make it hard to complete everyday activities, even when taking the available medications. In the CRESCENDO survey, NT1 symptoms were felt even though the survey’s participants were taking available treatments.

All 203 participants in the CRESCENDO survey were taking available treatments for NT1, including wake promoting agents, oxybates, and stimulants. Even though they were taking these medications, 77% had cataplexy, 64% had EDS, 74% had cognitive impairment, and 68% had an average to difficult time concentrating. Participants also felt professional, social, and day-to-day burdens because of their symptoms.

A new approach

Orexin is a protein that helps the brain manage the sleep-wake cycle. This cycle is important for keeping people awake and asleep at the right time. Low levels of orexin are a known cause of NT1. Scientists believe an orexin-based approach may treat narcolepsy directly instead of just treating the symptoms.

Who can join the SAPPHIRE Clinical Trial?

The SAPPHIRE Clinical Trial needs volunteers to help us understand how well cleminorexton works. To join, you must be:

  • 18 to 70 years old
  • Diagnosed with NT1 or NT2
  • Within the body mass index (BMI) range of ≥17.0 and ≤45 kg/m2
  • Able and willing to come off current narcolepsy medications

This is not a complete list of study requirements. A study doctor will review the full list of requirements with you.

What will it be like to volunteer for the SAPPHIRE Clinical Trial?

If you qualify for the study, you will stop taking your current NT1 or NT2 medications. You will be randomly assigned to receive a study drug (cleminorexton or a placebo). The SAPPHIRE Clinical Trial is double-blinded, meaning no one will know which study drug you are taking. In the case of an emergency, your study doctor will be able to find out which study drug you are taking.

Study staff will give you oral capsules to take by mouth twice a day. The first dose is taken when you wake up. The second dose is taken about four hours later, as directed by the study doctor.

During the Treatment Period, you will attend clinic visits (some overnight). You will complete assessments and activities, including physical exams, lab tests, vital sign measurements, and daily diaries.

This is not a complete list of study requirements. A study doctor will review all assessments, activities, and visits in detail.

How long will the SAPPHIRE Clinical Trial last?

The study will have three periods:

Screening Period: up to 7 weeksYou will complete assessments to confirm if you qualify for the study.
Treatment Period: 12 weeksIf you qualify for the study, you will take either cleminorexton or a placebo (your study drug).
Safety Follow-Up Period: 1 weekYou will attend a safety follow-up visit if you do not choose to join the LTE study at the end of the Treatment Period.

You may be able to enroll in a long-term extension study (LTE) at the end of the Treatment Period. The LTE will allow for open label access to cleminorexton (meaning everyone will receive cleminorexton and no one will receive a placebo).

If you join the LTE study, you can start right away and do not need to complete the Safety-Follow-Up Period for this study.

Frequently asked questions

What is an investigational drug?

An investigational drug, like cleminorexton, is one in clinical testing. These drugs have not been approved by regulatory agencies, such as the United States Food and Drug Administration (FDA) or European Medicines Agency (EMA). As such, investigational drugs are not yet available outside of clinical trials.

What is a placebo?

A placebo looks like the investigational drug but does not contain any active ingredient. It helps doctors understand how well the investigational drug is working.

What is a long-term extension (LTE) study?

An LTE study helps collect data about a study drug over a longer period of time.

Do you have to pay for the study drug?

No, if you participate in the SAPPHIRE Clinical Trial you will not pay for the study drug or for any tests or procedures related to the study. You may be reimbursed for some costs, like meals and transportation. A member of the study staff will review all details with you.

Are there risks to volunteering for the study?

Every clinical trial has potential risks. Study staff will inform you of the risks of the trial before you are asked to give your consent to volunteer. Study doctors will closely monitor you during the study.

Where does the study take place?

Meris Clinical Research – Brandon
310 Oakfield Dr., Brandon, FL 33511
Phone: (813) 413-7218

Study team:

  • Dr. Dragos Zanchi, MD, FCCP, FAASM
  • Dr. Rafael Martinez, MD, FCCP
  • Krista Ziesman-Weaver, APRN
  • Lauren Kornacker, APRN

How do I apply?

Call Meris Clinical Research at (813) 413-7218 or complete the form on this page. A member of the study staff will review the study requirements with you.

You can help advance research for new potential treatments

Clinical trials are an important part of medical research, and new treatments could not be made available without them. Thank you for your time and support of the SAPPHIRE Clinical Trial.

Study details

Study nameSAPPHIRE Clinical Trial
Investigational drugcleminorexton
SponsorCentessa Pharmaceuticals
Protocol numberORX750-004
ClinicalTrials.gov numberNCT07598708
PhasePhase 2/3
Therapeutic areaSleep

Interested in participating in one of our clinical studies?

Image related to content